269. From great moderation to great volatility

Agbioscience

Global venture capital deal volume has fallen by 50% worldwide since peaking in the first quarter of 2022 – that’s according the global analyst firm CB Insights. Despite the decline, companies are raising capital. Today’s guest is here to share more about the current fundraising environment and what it means for innovation. Audre Kapacinskas, principal with S2G Ventures – the second most active agtech investor in America – joins us to talk investment across the entire value chain.

The daughter of an immigrant, Audre found her love for the food space when her mother opened up a bakery. That love took her on a professional journey to s2g Ventures where she focuses on helping their nearly 100 portfolio companies in food and agriculture thrive. She gets into solutions that create more balance across the value chain, removing the brunt of risk and cost to the farmer and aligning financial incentives to drive impact. Audre also talks about the importance of having farmers at the discussion table when it comes to innovation and what she’s seeing in terms of valuation, time to close and how entrepreneurs and investors are working together during a tumultuous time; she stresses patient capital in the agbiosciences as being important.

So what will the capital landscape look like in the future? Audre talks big corporate investment, aligning incentives for all stakeholders to drive innovation and how she sees the agbiosciences evolving from an era of great moderation to one of great volatility.